Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
Abstract We performed the first in-depth, comparative and prospective biomonitoring of Multiple Myeloma (MM) patients (N = 39) receiving ciltacabtagene autoleucel (cilta-cel) or idecabtagene vicleucel (ide-cel) chimeric antigen receptor T cells (CAR T) in the real-world setting. In cilta-cel patient...
Saved in:
| Main Authors: | Djordje Atanackovic, Tim Luetkens, Dina Schneider, Peirong Hu, Xu Wang, Amol C. Shetty, Luke Tallon, Imari Patel, Rohan Singh, Etse Gebru, Rediet Mulatu, Destiny Omili, Daniel Yamoah, Xiaoxuan Fan, Aerielle Matsangos, Patricia Lesho, Kenneth A. Dietze, Ariel A. Fromowitz, Kim G. Hankey, Saurabh Dahiya, Jean A. Yared, Nancy M. Hardy, Rima Koka, Michael E. Kallen, Ashraf Badros, Aaron P. Rapoport, Mehmet H. Kocoglu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-60980-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
by: Maximilian Merz, et al.
Published: (2025-01-01) -
Intrathecal chemotherapy for ciltacabtagene autoleucel–associated movement and neurocognitive toxicity
by: Kaitlin Kelly, et al.
Published: (2025-07-01) -
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel
by: Satabdi Saha, et al.
Published: (2025-07-01) -
Cilta-cel CAR T cells as an effective and well tolerated treatment for POEMS: a case study
by: Matthew Williams, et al.
Published: (2025-06-01) -
Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience
by: Aaron Trando, et al.
Published: (2024-12-01)